皮下自己投与用注射装置の世界市場 (2028年まで)

当レポートでは、世界の皮下自己投与用注射装置の市場について分析し、市場の基本構造や最新情勢、主な促進・抑制要因、全体的な市場規模の動向見通し (2028年まで)、主な治療領域別の詳細動向 (全9種類)、主要企業のプロファイルと事業展開状況、主な事業協力・提携の動き、といった情報を取りまとめてお届けいたします。

目次

エグゼクティブサマリー

• 皮下自己投与用注射装置
• エグゼクティブサマリー
• 市場機会
• デリバリー市場力学
• 注射薬の経済性
• 注射装置の成長促進要因
• プレフィルドシリンジの急増
• 自己管理の傾向
• 人口動態の変化
• 使い捨てデバイスの設計の革新
• バイオ医薬品の増加
• 治療用モノクローナル抗体
• 治療需要の推進要因
• 競合情勢
• 危険因子
• 自動注射器：商用デバイス
• 手動注射器
• 自動注射器
• 使い捨て型自動注射器
• Molly (SHL Medical)
• Molly RNS (SHLMedical)
• Bertha (SHL Medical)
• Maggie (SHL Medical)
• Amber (SHL Medical)
• SafeLock (SHL Medical)
• VSDI +NIT (SHL Medical)
• SDI MIX +NIT (SHL Medical)
• Syrina S (Consort Medical)
• Syrina AS (Consort Medical)
• AutoJect 2 (Owen Mumford)
• SelfDose (West Pharmaceutical Services)
• Flexi-Q PFS (Elcam Medical)
• OTS Autoinjector (Consort Medical)
• Pro-Ject (Aptar)
• Consort Medical ASI
• Ypsomed VarioJect
• Rotaject Technology (SHL Medical)
• Viscala Autoinjector (Consort Medical)
• Flexi-Q HV (Elcam Medical)
• Intevia (Becton Dickinson)
• Antares Pharma Autoinjectors
• Dali Medical Devices
• 開発段階の自動注射器
• NIS Autoinjector (Midas Pharma)
• ArQ - (Oval Medical)
• Wirelessly Enabled Autoinjectors
• BETACONNECT (Bayer)
• RebiSmart (Merck Serono)
• 自動注射器：主要製品の仕様
• アルスマ/スマトリプタン自動注射器
• Sumatriptan (Dr. Reddy's)
• Rebif/Rebidose (Merck Serono)
• Aimovig (Amgen/Novartis)
• Enbrel Mini AutoTouch (Amgen)
• Pegasys Proclick (Genentech/Roche)
• Otrexup (Antares Pharma)
• Evzio (Kaleo)
• 自動注射器の設計要素
• 材料選択の問題
• 部品点数とデバイスの費用
• 安全機能
• 針挿入深度
• フェイルセーフアクティベーション
• 投与量検査・注射確認
• 凍結乾燥薬・再構成
• 人間工学・エルゴノミクス
• ペン型注射器
• ペン型注射器の設計選択要因
• 標準型ペンプラットフォーム
• Haselmeier
• Becton Dickinson
• Owen Mumford
• Autoject2
• Ypsomed
• SHL Medical
• カスタム型ペンの設計
• 再利用型ペン
• 二室型ペン
• 実用化されたペン製品
• Genotropin Pen
• Humatro-Pen/Humatro Pen 3
• Norditropin
• NordiPenmate
• Nutropin AQ Pen
• Omnitrope
• One.Click
• Lantus/Toujeo (インスリングラルギン)
• Diapen
• Gansulin Pen
• Flexpen (Novo Nordisk)
• Humalog Pen/KwikPen
• HumaPen Memoir
• HumaPen Luxura HD
• NovoPen (Novo Nordisk)
• SoloStar
• Byetta Pen
• Bydureon
• SymlinPen
• Saxenda (リラグルチド)
• Tanzeum (アブリグルチド)
• Trulicity (デュラグルチド)
• Victoza (リラグルチド)
• 副甲状腺ホルモン
• Forteo Pen
• Preotact/Preos
• Natpara
• 生殖ホルモン
• Follistim/Puregon Pen
• Gonal-f
• ウェアラブルデバイス：製品の分析と評価
• Libertas (Becton Dickinson)
• Patch Pump (Sensile Medical)
• SmartDose (West Pharmaceuticals)
• Neulasta OnPro Injector (Insulet/Amgen)
• YpsoDose (Ypsomed)
• Electronic Semi-disposable
• E3D Patch Pump (Elcam)
• 使い捨て型機械的部品
• enFuse (Enable Injections)
• Captive Devices
• sc2Wear Infusor (scPharmaceuticals)
• PatchPump (SteadyMed)
• Wireless Data
• 主な治療薬：分野別の分析
• アナフィラキシー/対策
• 自己免疫疾患
• 関節リウマチ
• 乾癬
• 多発性硬化症
• Exenatide (Byetta)
• Bydureon
• Pramlinitide (Symlin)
• Abliglutide (Tanzeum)
• 肝炎
• ホルモン
• 骨粗鬆症
• 市場要因
• 規制の課題
• デバイスのブランディング
• 患者のアドヒアランスと使いやすさ
• 医療経済
• 企業プロファイル

Evolution in Therapeutic Care

Because of the ongoing need for repeat dosing posed by chronic diseases, these indications represent significant drug volume and revenue opportunities, while simultaneously challenging the industry to develop products that meet the unique needs of the non-professional caregiver. For drugs designed to be administered by the patient, therapy-specific packaging is improving adherence and treatment outcomes. In the area of delivery, reusable injection devices designed to accept prefilled syringes or drug cartridges are improving ease-of-use and increasing the alternative device share of the growing self-injection market.

What You Will Learn:

• Provides detailed analysis of subcutaneous drug products, drug delivery and device strategies, and product development factors

• Assesses key markets, market dynamics and market demographics

• Analyzes therapeutic demand drivers and evaluates SC drug products in nine key therapeutic segments

• Provides market data and forecasts to 2028

• Profiles market sector participants, their product development activities, business strategies, and corporate alliances and affiliations

• Assesses the importance of alliances and partnerships on subcutaneous drug product commercialization

• Evaluates the impact of economic, technology, and regulatory factor

Table of Contents

Executive Summary

• Injection Devices for Subcutaneous Self-administration
• Executive Summary
• The Market Opportunity
• Delivery Market Dynamics
• The Economics of Injectable Drugs
• What's Driving the Growth in Injectable Devices?
• Prefilled Syringes Proliferating
• The Trend toward Self-Administration
• Shifting Demographics
• Innovation in Disposable Device Designs
• Proliferation of Biological Drugs
• Therapeutic Monoclonal Antibodies
• Therapeutic Demand Drivers
• Competitive Landscape
• Risk Factors
• Autoinjectors - Commercial Devices
• Manual Injection Autoinjectors
• Automated Injection Autoinjectors
• Disposable Autoinjectors
• Molly (SHL Medical)
• Molly RNS (SHLMedical)
• Bertha (SHL Medical)
• Maggie (SHL Medical)
• Amber (SHL Medical)
• SafeLock (SHL Medical)
• VSDI +NIT (SHL Medical)
• SDI MIX +NIT (SHL Medical)
• Syrina S (Consort Medical)
• Syrina AS (Consort Medical)
• AutoJect 2 (Owen Mumford)
• SelfDose (West Pharmaceutical Services)
• Flexi-Q PFS (Elcam Medical)
• OTS Autoinjector (Consort Medical)
• Pro-Ject (Aptar)
• Consort Medical ASI
• Ypsomed VarioJect
• Rotaject Technology (SHL Medical)
• Viscala Autoinjector (Consort Medical)
• Flexi-Q HV (Elcam Medical)
• Intevia (Becton Dickinson)
• Antares Pharma Autoinjectors
• Dali Medical Devices
• Development-stage Autoinjectors
• NIS Autoinjector (Midas Pharma)
• ArQ - (Oval Medical)
• Wirelessly Enabled Autoinjectors
• BETACONNECT (Bayer)
• RebiSmart (Merck Serono)
• Selected Product Specific Autoinjectors
• Alsuma/Sumatriptan Autoinjector
• Sumatriptan (Dr. Reddy's)
• Rebif/Rebidose (Merck Serono)
• Aimovig (Amgen/Novartis)
• Enbrel Mini AutoTouch (Amgen)
• Pegasys Proclick (Genentech/Roche)
• Otrexup (Antares Pharma)
• Evzio (Kaleo)
• Autoinjector Device Design Factors
• Material Selection Issues
• Part Counts and Device Cost
• Safety Features
• Needle Insertion Depth
• Failsafe Activation
• Dose Inspection/Injection Confirmation
• Lyophilized Drugs/Reconstitution
• Human Engineering/Ergonomics
• Pen Injectors
• Pen Injector Design Selection Factors
• Standardized Pen Platforms
• Haselmeier
• Becton Dickinson
• Owen Mumford
• Autoject2
• Ypsomed
• SHL Medical
• Custom Pen Designs
• Reusable Pens
• Dual Chamber Pens
• Commercial Pen Products
• Genotropin Pen
• Humatro-Pen/Humatro Pen 3
• Norditropin
• NordiPenmate
• Nutropin AQ Pen
• Omnitrope
• One.Click
• Lantus/Toujeo (Insulin Glargine)
• Diapen
• Gansulin Pen
• Flexpen (Novo Nordisk)
• Humalog Pen/KwikPen
• HumaPen Memoir
• HumaPen Luxura HD
• NovoPen (Novo Nordisk)
• SoloStar
• Byetta Pen
• Bydureon
• SymlinPen
• Saxenda (Liraglutide)
• Tanzeum (Abliglutide)
• Trulicity (Dulaglutide)
• Victoza (Liraglutide)
• Parathyroid Hormone
• Forteo Pen
• Preotact/Preos
• Natpara
• Reproductive Hormones
• Follistim/Puregon Pen
• Gonal-f
• Wearable Devices - Product Analysis and Assessments
• Libertas (Becton Dickinson)
• Patch Pump (Sensile Medical)
• SmartDose (West Pharmaceuticals)
• Neulasta OnPro Injector (Insulet/Amgen)
• YpsoDose (Ypsomed)
• Electronic Semi-disposable
• E3D Patch Pump (Elcam)
• Mechanical Disposable
• enFuse (Enable Injections)
• Captive Devices
• sc2Wear Infusor (scPharmaceuticals)
• PatchPump (SteadyMed)
• Wireless Data
• Key Therapeutic Sector Analysis
• Anaphylaxis/Countermeasures
• Autoimmune Diseases
• Rheumatoid Arthritis
• Psoriasis
• Multiple Sclerosis
• Exenatide (Byetta)
• Bydureon
• Pramlinitide (Symlin)
• Abliglutide (Tanzeum)
• Hepatitis
• Hormones
• Osteoporosis
• Market Factors
• Regulatory Issues
• Device Branding
• Patient Adherence and Ease of Use
• Healthcare Economics
• Company Profiles